3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
3
Withdrawn
2
Unknown
2
Completed
2
Terminated
1
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
19
Prostatic Neoplasms, Castration-Resistant
1
Prostate Cancer Metastatic
1
NSCLC Harboring NRG1 Fusion
1
Metastatic Castration-resistant Prostate Cancer
1
Metastatic Castration Resistant Prostate Cancer
1
Castrate-resistant Prostate Cancer
1
Adenocarcinoma
1
Interventions
enzalutamide
4
abiraterone
2
Docetaxel
2
tasquinimod
1
sabizabulin
1
olaparib
1
ipatasertib
1
darolutamide
1
atezolizumab
1
Nivolumab
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Prostatic Neoplasms, Castration-Resistant
×
Abiraterone Acetate
×
Clear all
NCT04844749
2024-02-05
VERACITY
Veru Inc.
Phase 3
Terminated
105 enrolled